Adicet Bio shares rise on FDA Fast Track Designation for ADI-001

Investing.com -- Adicet Bio shares jumped 6.4% premarket after the company announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its investigational therapy ADI-001 for the treatment of systemic sclerosis (SSc).

ADI-001 is a CAR T cell therapy that targets CD20 to treat autoimmune diseases.

Fast Track Designation is intended to accelerate the development and regulatory review of drugs aimed at treating serious conditions with unmet medical needs.

The designation provides Adicet Bio with several potential advantages, including more frequent FDA interactions, eligibility for priority review, and the possibility of accelerated approval if clinical data supports it.

This milestone strengthens Adicet Bio’s position in the cell therapy space, particularly in autoimmune diseases and cancer, where the company is focused on developing novel gamma delta T cell-based treatments.

The stock’s premarket jump reflects investor optimism about the regulatory progress of ADI-001 and its potential to address systemic sclerosis.

You May Also Be Interested In

• Integer Holdings stock surges 21% on KKR takeover report
• UBS sees upside in SK Hynix stock on high memory profitability
• BofA sees inflation markets as Fed credibility measure